444 related articles for article (PubMed ID: 35740570)
21. In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles.
Abreu TR; Biscaia M; Gonçalves N; Fonseca NA; Moreira JN
Adv Exp Med Biol; 2021; 1295():271-299. PubMed ID: 33543464
[TBL] [Abstract][Full Text] [Related]
22. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy.
Xu X; Wu Y; Qian X; Wang Y; Wang J; Li J; Li Y; Zhang Z
Adv Healthc Mater; 2022 Jan; 11(1):e2101428. PubMed ID: 34706400
[TBL] [Abstract][Full Text] [Related]
23. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
24. ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
Zheng M; Liu Y; Wang Y; Zhang D; Zou Y; Ruan W; Yin J; Tao W; Park JB; Shi B
Adv Mater; 2019 Sep; 31(37):e1903277. PubMed ID: 31348581
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting Solid Tumor Growth In Vivo by Non-Tumor-Penetrating Nanomedicine.
Lv S; Tang Z; Song W; Zhang D; Li M; Liu H; Cheng J; Zhong W; Chen X
Small; 2017 Mar; 13(12):. PubMed ID: 28079981
[TBL] [Abstract][Full Text] [Related]
26. Smart transformable nanomedicines for cancer therapy.
Wang Y; Li S; Wang X; Chen Q; He Z; Luo C; Sun J
Biomaterials; 2021 Apr; 271():120737. PubMed ID: 33690103
[TBL] [Abstract][Full Text] [Related]
27. Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs.
Ahmed T; Liu FF; Lu B; Lip H; Park E; Alradwan I; Liu JF; He C; Zetrini A; Zhang T; Ghavaminejad A; Rauth AM; Henderson JT; Wu XY
Mol Pharm; 2022 Jun; 19(6):1722-1765. PubMed ID: 35587783
[TBL] [Abstract][Full Text] [Related]
28. Targeting tumor associated macrophages: The new challenge for nanomedicine.
Andón FT; Digifico E; Maeda A; Erreni M; Mantovani A; Alonso MJ; Allavena P
Semin Immunol; 2017 Dec; 34():103-113. PubMed ID: 28941641
[TBL] [Abstract][Full Text] [Related]
29. Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers.
Raza F; Zafar H; You X; Khan A; Wu J; Ge L
J Mater Chem B; 2019 Dec; 7(48):7639-7655. PubMed ID: 31746934
[TBL] [Abstract][Full Text] [Related]
30. Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.
Shi NQ; Li Y; Zhang Y; Li ZQ; Qi XR
Int J Nanomedicine; 2018; 13():5537-5559. PubMed ID: 30271146
[TBL] [Abstract][Full Text] [Related]
31. Transcytosis of Nanomedicine for Tumor Penetration.
Liu Y; Huo Y; Yao L; Xu Y; Meng F; Li H; Sun K; Zhou G; Kohane DS; Tao K
Nano Lett; 2019 Nov; 19(11):8010-8020. PubMed ID: 31639306
[TBL] [Abstract][Full Text] [Related]
32. Peptide-decorated polymeric nanomedicines for precision cancer therapy.
Sun H; Dong Y; Feijen J; Zhong Z
J Control Release; 2018 Nov; 290():11-27. PubMed ID: 30290243
[TBL] [Abstract][Full Text] [Related]
33. Sequential Intra-Intercellular Delivery of Nanomedicine for Deep Drug-Resistant Solid Tumor Penetration.
He Y; Cong C; Li L; Luo L; He Y; Hao Z; Gao D
ACS Appl Mater Interfaces; 2020 Feb; 12(8):8978-8988. PubMed ID: 32020804
[TBL] [Abstract][Full Text] [Related]
34. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.
Peng C; Huang Y; Zheng J
J Control Release; 2020 Jun; 322():64-80. PubMed ID: 32194171
[TBL] [Abstract][Full Text] [Related]
35. Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration.
Guo J; Zeng H; Chen Y
Mol Pharm; 2020 Apr; 17(4):1028-1048. PubMed ID: 32150417
[TBL] [Abstract][Full Text] [Related]
36. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
37. An injectable and tumor-specific responsive hydrogel with tissue-adhesive and nanomedicine-releasing abilities for precise locoregional chemotherapy.
Wu D; Shi X; Zhao F; Chilengue STF; Deng L; Dong A; Kong D; Wang W; Zhang J
Acta Biomater; 2019 Sep; 96():123-136. PubMed ID: 31247382
[TBL] [Abstract][Full Text] [Related]
38. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
39. Dual-drug nanomedicine with hydrophilic F127-modified magnetic nanocarriers assembled in amphiphilic gelatin for enhanced penetration and drug delivery in deep tumor tissue.
Lai YH; Chiang CS; Kao TH; Chen SY
Int J Nanomedicine; 2018; 13():3011-3026. PubMed ID: 29861633
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management.
Huo D; Jiang X; Hu Y
Adv Mater; 2020 Jul; 32(27):e1904337. PubMed ID: 31663198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
